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Abstract 
Background: GnRH agonist and antagonist were developed to control the 
premature release of LH surge. There is some difference between two protocols. 
Objective: We compared the outcome of frozen-thawed embryo transfer in infertile 
women who used GnRH agonist or antagonist protocol for previous COH cycle and 
evaluation of any adverse effect of GnRH antagonist on oocyte and embryo. 
Materials and Methods: The study group included all infertile women who referred 
to Yazd Research and Clinical Center for Infertility. Overall 20-35 years old women 
who were candidate for frozen-thawed embryo transfer with regard to inclusion and 
exclusion criteria were participated in the study. The patients based on previous 
control ovarian stimulation (COH) protocol divided in to two groups: GnRH agonist 
long protocol (n=165) and GnRH antagonist multiple dose protocol (n=165). 
Frozen-thawed embryos were transferred after endometrial preparation in both 
groups. Main outcome measures were: implantation, chemical and clinical 
pregnancy rate. 
Results: The implantation and clinical pregnancy rate following cryopreserved 
embryo transfer in GnRH agonist group and antagonist group were 16.3% vs. 15.7% 
(p=0.806) and 38.1% (63/165) vs. 36.9% (61/165) (p=0.915) and chemical 
pregnancy rate was 44.8% (74/165) vs. 43.6% (72/165) (p=0.915) respectively.  
Conclusion: There was no statistically difference between two groups in terms of 
implantation and pregnancy rate. Although pregnancy rate in fresh embryo transfer 
in antagonist cycles was lower than agonist groups, Therefore decrease in these 
parameters might be due to detrimental effect of GnRH antagonist on the 
endometrium, not embryo or oocyte. 
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Introduction 
 
nRH agonist has been the standard 
protocol for ovulation induction in in 
vitro fertilization cycles for 20 years 
ago. However, GnRH agonist has some 
complication including: estrogen deprivation 
symptom, need more gonadotropin 
consumption, ovarian cyst formation. Pituitary 
function was not immediately returned 
following GnRH agonist discontinuation.  
After the discovery of GnRH (Gonadotropin 
Releasing Hormone) agonists and their use in 
pituitary desensitization, cycle cancellation 
due to premature LH surge was significantly 
decreased. During recent decades a new 
generation of GnRH antagonist have been 
introduced which can competitively block 
GnRH receptors and cause rapid LH surge 
inhibition (1-4). In some study GnRH agonist 
have been compared with GnRH antagonist 
for COS in infertile patients as the decrease of 
pregnancy rate in cycles using GnRH 
antagonist protocol was reported (5, 6). But 
decreasing of implantation and pregnancy 
rates following use of GNR antagonists are 
still controversial (7, 8). Lower pregnancy rate 
following antagonist protocol may be due to 
GnRH receptors which have been discovered 
in extra pituitary tissues including ovary, 
endometrium, myometrium and embryo.  
These receptors may inhibit by the extra 
pituitary GnRH antagonist effects and leading 
to decrease pregnancy rate. Decreasing of 
pregnancy rate due to detrimental effect of 
GnRH antagonist on oocyte quality or 
endometrial receptivity is still debate (7, 9-13). 
Transfer of frozen-thawed embryo makes a 
G 
Eftekhar et al 
298                                                        Iranian Journal of Reproductive Medicine Vol. 10. No. 4. pp: 297-302, July 2012 
possibility to eliminate any adverse effect of 
GnRH antagonist on endometrium that may 
cause lower pregnancy rate. Therefore 
assessment of ART outcome using 
cryopreserved-thawed embryos, provide an 
opportunity to compare the effect of GnRH 
antagonist and agonist protocols in the same 
situation.  
In this study, we evaluate ART outcomes in 
frozen-thawed embryo transfer cycles in the 
two groups of patients who have used GnRH 
agonist or antagonist in previous controlled 
ovarian hyper stimulation (COH). 
 
Materials and methods 
 
This retrospective cohort study was 
conducted at Yazd Research and Clinical 
Center for Infertility, Shahid Sadoughi 
University of Medical Sciences, between 
January 2009 and June 2011. The study was 
approved by ethics committee. 330 couples 
were participated in this study. All women had 
previously undergone controlled ovarian 
stimulation with standard long agonist protocol 
or antagonist protocol and in-vitro fertilization 
(IVF) or intracytoplasmic sperm injection 
(ICSI) with embryo cryopreservation was done 
for them. All of the patients failed fresh 
embryo transfer, and then were candidate for 
cryopreserved embryo transfer.  
In group I (agonist group), Decapeptyl 
(Decapeptyl® 0.1 mg, Ferring , Germany) was 
started 0.1 mg per day subcutaneously from 
previous mid-luteal phase. Decapeptyl dose 
was decreased to 0.05 mg/day on the first day 
of menstrual bleeding and continued until the 
day of HCG injection. Ovarian stimulation was 
done from day 2 of menstrual cycle with daily 
administration (150 IU) of human recombinant 
follicle-stimulating hormone (Gonal-f, serono, 
Aubnne, Switzerland) and continued until the 
day of HCG injection. Ovarian response was 
monitored using serial ultrasound 
examination. 
Ovarian stimulation was started in group II 
(antagonist group) from second day of 
menstrual cycle with (150 IU) of human 
recombinant follicle-stimulating hormone 
(Gonal-f, serono, Aubnne, Switzerland) 
monitoring by serial vaginal sonography was 
done. When dominant follicles reached to      
14 mm in mean diameter, 0.25mg/day of 
GnRH antagonist (cetrotide, sereno) was 
started and continued until the day of HCG 
injection. In both groups when at least two 
follicles with a mean diameter of 17 mm or 
one leading follicle was larger than 18 mm, 
were observed 10000 IU HCG (Pregnyl, 
Organon, Netherland) was injected. For all of 
the patients’ endometrial thickness and serum 
E2 levels were measured in the day of HCG 
injection.  
A three-layered endometrium was seen in 
all of the patients. Oocyte retrieval was done 
34-36 hours after HCG injection, using a 17-
gauge needle under vaginal ultrasonography 
guidance and conventional IVF or 
intracytoplasmic sperm injection (ICSI) was 
done appropriately. 
More than 3 embryos were not transferred 
in fresh cycles and all the excess embryos 
with <30% fragmentation was cryopreserved 
by vitrification method. Women with age      
>35 years, BMI >30, previous ovarian hyper 
stimulation syndrome, history of D.M. and 
thyroid disease and history of sever 
endometriosis were excluded from the study. 
Oocyte donation cycles were excluded from 
the study. Only patients that had implantation 
failure after fresh embryo transfer were 
participated in the study. Frozen embryo cycle 
was used at least 2 months after fresh cycle.  
Endometrial preparation in both group was 
similar, estradiol valerate (Estradiol valerate, 
Aburaihan CO, Tehran, Iran) was taken orally 
at the dose of 6 mg per day from the second 
day of menstrual cycle. In day 13 of cycle, an 
ultrasound examination was performed. It was 
used to assess endometrial thickness. When 
the endometrial thickness reached more than 
8 mm in diameter, 100 mg progesterone in oil 
(progesterone, aburaihan, CO, Tehran, Iran) 
was injected daily. Estradiol and progesterone 
consumption were continued until the 
documentation of fetal heart activity by 
ultrasound.  
Thawing of the embryos in both groups 
was performed 2 days after beginning of 
progesterone injection. In both group embryos 
transfer 1 day after thawing by using a 
labotect catheter (Labotect, Gottingen, 
Germany). Embryo quality was assessing 
using the modified cumulative embryo score 
(14). Good quality embryo was transferred by 
one of the expert specialist. Primary outcome 
was defined as ongoing pregnancy. 
Implantation was defined by number of 
gestational sacs per number of transferred 
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embryos. Chemical pregnancy was defined by 
serum β-hCG >50 IU/L, 12 days after embryo 
transfer, clinical pregnancy was defined by 
observation of fetal heart activity by 
transvaginal ultrasonography 5 weeks after 
positive β-hCG.  
 
Statistical analysis 
The student t-test was used to continuous 
variable and chi-square test was used to 
compare attributive variables. We used 
statistical software SPSS Version 16 (SPSS 
Inc., Chicago, USA). Our statistical significant 
was set at p<0.05.  
 
 
Results 
 
Three hundred thirty couples were 
participated in this study and patients were 
divided into two groups 165 patients in agonist 
group and 165 patients in antagonist group. 
Demographic and infertility characteristic are 
shown in table I, female age, duration of 
infertility, basal FSH, BMI and etiology of 
infertility were similar in both groups. The 
cycle characteristics and outcome of ART are 
showed in table II. No statistically differences 
were reported in implantation, chemical and 
clinical pregnancy. 
 
 
Table I.  Basic characteristics of patients of patients in two groups. 
Variables Agonist group 
 (n=165) 
Antagonist group 
Mean±SD (n=165) 
 
p-value 
Female age (years)* 
 
29.8 ± 4.48 29.5 ± 4.55 0.942 
Duration of infertility (years)*  
 
8.65 ± 4.67 8.12 ± 3.80 0.266 
Basal FSH (IU/L)*  
 
5.61  ± 2.0 5.68 ± 1.72 0.812 
BMI (Kg/m2)*  
 
23.45 ± 3.4 23.65 ± 2.3 0.336 
Etiology of infertility, n (%) 
 
0.099 
 
Male 
 
74 (44.8%) 60 (36.4%)  
 
PCO 
 
55 (33.3%) 54 (32.7%)  
 
Tubal 
 
9 (5.5%) 9 (5.5%)  
 
Unexplained 
 
18 (10.9%) 21 (12.7%)  
 
Mix 
 
9 (5.5%) 21 (12.7%)  
*(Mean±SD) 
 
 
Table II. Cycle characteristic and ART outcome in two groups. 
Variables Agonist group 
(n=165) 
Antagonist group 
(n=165) 
 
p-value 
Endometrial thickness (mm)* 
 
9.45 ± 1.1 9.51 ± 1.66 0.639 
Duration of estradiol consumption (day)* 
 
17.15 ± 1.37 17.32 ± 1.10 0.219 
No. of embryos transferred* 
 
2.65 ± 0.73 2.92 ± 0.9 0.32 
Implantation rate (%) 
 
16.3% 15.7% 0.806 
Chemical pregnancy rate, n (%) 
 
74 (44.8%) 72 (43.6%) 0.825 
Clinical pregnancy rate, n (%) 
 
63 (38.1%) 61 (36.9%) 0.915 
*(Mean±SD) 
 
Discussion 
 
GnRH agonist are used as the standard 
treatment protocol in controlled ovarian 
stimulation cycles, but in recent years by 
introducing GnRH antagonists, new horizons 
was created in the treatment of infertile 
patients. There are several advantages over 
GnRH antagonists: rapid suppression of the 
pituitary due to competitive inhibition of GnRH 
receptor,  their   effect   is   rapid   and   dose- 
 
dependent, have no initial flair effect, 
decreased length of treatment cycle, reduce 
the amount of gonadotropin consumption, 
reduce OHSS risk, reduce estrogen 
deprivation symptoms (1-4, 8, 15, 16).  
In this study, we detected no difference in 
cryopreserved-thawed implantation, chemical 
and clinical pregnancy rate, between GnRH 
agonist and antagonist protocol. Previous 
studies on cryopreserved-thawed obtained 
similar findings, in a retrospective study on 
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406 infertile women found no significant 
difference in the pregnancy rate per thawed 
cycles and cumulative live birth rate but in 
term of post thawed blastocyst survival, GnRH 
agonist group was higher (17). Bahçeci et al 
published 714 infertile patients who 
transferred fresh embryo or frozen-thawed 
embryo showed no difference between 
agonist or antagonist groups in implantation 
and pregnancy rate in cryopreserved-thawed 
group but in fresh embryo transfer group, 
implantation and pregnancy rate was 
significantly different (8). 
Some studies represented that GnRH 
antagonist can decrease ovarian paracrine 
activity by decreasing in insulin-like growth 
factor (IGF) and epidermal growth factor 
(EGF) biosynthesis, that are essential for 
folliculogenessis (7, 18-20), but another 
authors proposed that GnRH antagonists do 
not have detrimental effect on ovarian 
steroidogenesis or IGF biosynthesis and also 
represented that the intrafollicular levels of 
IGF-I and EGF do not seem to be influenced 
by the GnRH antagonist (21, 22). 
In recent studies the effect of antagonists 
on the endometrium has been investigated 
expression of several growth factors and their 
receptors on the endometrium that seems to 
be effective in implantation (i.e., transforming 
growth factor, fibronectin and L-selectin) were 
investigated and demonstrated that GnRH 
analogues alters the expression of 
transforming growth factor-β (TGF-β) and 
receptors in endometrial cells and also GnRH 
analogues and TGF-β through MAPK/ERK 
Lead to changes in fibronectin expression in 
endometrial cells, a molecular mechanism that 
could influence embryo implantation (23). 
Matrix metalloproteinase (MMP) and their 
specific inhibitors, role in Trophoblastic cell 
invasion into the endometrium and therefore 
they are important to implantation. GnRH 
Increases expression of MMP-9 and MMP-2, 
but GnRH antagonist inhibits these enzymes 
and therefore can disrupt in implantation (24). 
GnRH antagonists as agonist are effective 
in inhibiting LH surge. Since the GnRH 
receptors were discovered in tissues outside 
the pituitary including: ovary, endometrium, 
myometrium and embryo, concerns have 
been increased about the detrimental effects 
of GnRH antagonists on extra pituitary tissue 
(9-12, 25). In several study these extra 
pituitary effect proposed as the cause of lower 
pregnancy rate in GnRH antagonist protocol 
but it is not obvious that witch extra pituitary 
effect of GnRH antagonist could be the main 
reason for a lower pregnancy rate. These 
concerns are according to several in-vitro 
studies suggesting decreased biosynthesis of 
growth factors caused by local action of GnRH 
antagonists (7, 26). 
GnRH Antagonist effect on the expression 
of HOXA10 genes in endometrium which is an 
important regulator of endometrial receptivity 
In comparison with GnRH agonist it was 
demonstrated that in GnRH antagonist group 
HOXA10 expression reduced in endometrial 
stromal cells (27). 
Frozen-thawed embryo transfer making 
possible a model to eliminate any detrimental 
effect of GnRH antagonist on endometrium 
that may cause lower pregnancy rate. 
Therefore assessment the cryopreserved-
thawed outcomes provide an opportunity to 
evaluate the effect of GnRH antagonist on 
oocyte and embryo. These findings suggest 
that the lower ART outcome in GnRH 
antagonist protocol seems to be due to 
detrimental effect of GnRH antagonist on 
endometrium not embryo or oocyte. According 
to result of our study, we also completely 
agree with previous study witch demonstrated 
that GnRH antagonist have no adverse effect 
on oocyte or embryo (3, 4, 8, 13, 28-30). 
In these studies the effect of antagonists on 
the results of ART cycles and their likely 
effects on the endometrium or embryo have 
been studied. Considering the results of these 
studies less success in ART cycles using 
GnRH antagonists compared with agonists 
does not seems to be due to adverse effects 
on the oocytes or embryo. The Main limitation 
of our study is its retrospective, despite this; 
we have shown that the two groups were 
similar in base line characteristics parameters: 
female age, BMI, basal FSH, cause of 
infertility, type of infertility, duration of infertility 
and number of embryo transfer. 
 
Conclusion 
 
In conclusion, pregnancy rate in fresh 
embryo transfer in antagonist cycles was 
lower than agonist groups. Therefore, decline 
in these parameters might be due to 
unfavorable effect of GnRH antagonist on the 
endometrium, not embryo or oocyte. GnRH 
antagonists are effective as agonists in 
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outcome of cryopreserved-thawed embryo 
transfer in terms of implantation and 
pregnancy rates. 
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